Tributary Capital Management LLC decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 7.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,400 shares of the medical research company’s stock after selling 1,500 shares during the period. Tributary Capital Management LLC’s holdings in Edwards Lifesciences Corporation were worth $2,057,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of EW. Quadrant Capital Group LLC raised its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the last quarter. YorkBridge Wealth Partners LLC purchased a new stake in Edwards Lifesciences Corporation during the first quarter valued at about $110,000. NEXT Financial Group Inc raised its stake in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the last quarter. Laurel Grove Capital LLC purchased a new stake in Edwards Lifesciences Corporation during the second quarter valued at about $201,000. Finally, TNB Financial purchased a new stake in Edwards Lifesciences Corporation during the second quarter valued at about $204,000. 84.15% of the stock is currently owned by institutional investors and hedge funds.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 116.19 on Monday. The firm has a market cap of $24.53 billion, a P/E ratio of 35.24 and a beta of 0.63. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The company has a 50-day moving average of $117.23 and a 200 day moving average of $104.41.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.20. The business had revenue of $842 million for the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.64 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Position Reduced by Tributary Capital Management LLC” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/07/edwards-lifesciences-corporation-ew-position-reduced-by-tributary-capital-management-llc-updated.html.

Several equities research analysts have recently issued reports on the stock. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Canaccord Genuity reissued a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research note on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 target price on the stock. Finally, Cowen and Company reissued an “outperform” rating and set a $135.00 target price (up from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $121.13.

In related news, VP Catherine M. Szyman sold 4,681 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. Insiders have sold 125,512 shares of company stock worth $14,460,159 in the last three months. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.